# Advent Life Sciences Fund IV

> Early-stage biotech and healthcare venture vehicle; British Business Bank agreed to an approximately €69.8M LP commitment on September 24, 2026 (converted estimate). Its institutional listing gives roughly €291M as a fundraising target, not funds raised. No first or final close was verified.

## Profile

- **Stage-based planning range:** $1M–$10M
- **Check-size evidence basis:** estimated
- **Founded:** N/A
- **Headquarters:** London, UK
- **AUM:** N/A
- **Rounds they lead:** N/A
- **Rounds they invest:** Seed, Series A, Series B

## Links

- [Website](https://adventls.com/)

## In-depth investment analysis

## Mandate
Separate from the manager's Growth Fund, Fund IV backs earlier-stage therapeutics, medtech and enabling healthcare platforms targeting major clinical needs. Geography is transatlantic.

## Capital, target and status
The British Business Bank [institutional profile](https://www.british-business-bank.co.uk/venture-link/advent-life-sciences-iv-fund) shows a roughly **€291M fundraising target**, converted using the September 24 ECB fixing (1 EUR = 0.85986 in original currency). It [agreed to commit](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-agrees-commit-ps135m-two-new-advent-life-sciences-funds) approximately **€69.8M**. The GP's full commitments, legal closing stage and actual close date **are not disclosed**; an agreement is not final close. No other institutional LP amounts are confirmed.

## Founder and LP fit
An illustrative early-stage company would demonstrate patent ownership, target/assay validation, preclinical reproducibility, milestone timeline and follow-on financing requirements. Neither a standard check size nor fee/carry, ownership target or fund return has been verified. Professional/institutional investor access is subject to private fund marketing rules, not retail subscriptions.

Related [manager](/fund/advent-life-sciences), [Growth Fund](/fund/advent-life-sciences-growth-fund). Sources: [bank release](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-agrees-commit-ps135m-two-new-advent-life-sciences-funds); [vehicle listing](https://www.british-business-bank.co.uk/venture-link/advent-life-sciences-iv-fund); [ECB](https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/index.en.html).

## Research sources

- [Fund IV target & status](https://www.british-business-bank.co.uk/venture-link/advent-life-sciences-iv-fund)
- [LP agreement statement](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-agrees-commit-ps135m-two-new-advent-life-sciences-funds)
- [Official FX reference](https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/index.en.html)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/fund/advent-life-sciences-fund-iv